OSUR
OraSure Technologies, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$3.49
−2.42%Aug 5, 2026, 20:05 UTC
OraSure Technologies announced its financial results for the second quarter of 2026 on August 5, 2026.
Aug 5, 2026, 00:00 UTC
OraSure Technologies repurchased $2 million of its common stock during Q2 2026, bringing total repurchases to $22 million under its $40 million authorized program.
Jul 21, 2026, 20:30 UTC
OraSure received Emergency Use Authorization from the FDA for its second generation Ebola rapid test that detects the Bundibugyo virus.
Source:Jun 11, 2026, 12:00 UTC
OraSure Technologies received FDA clearance for its Colli-Pee Dx Urine Collection Kit for use with Roche's STI tests on Roche's cobas molecular diagnostic systems.
Source:Jun 3, 2026, 00:00 UTC
OraSure Technologies elected John D. Bertrand, Steven K. Boyd, and Robert W. McMahon as Class II directors on June 3, 2026.